What is Cassidy Bio?
Cassidy Bio operates at the intersection of artificial intelligence and molecular biology, providing a sophisticated suite of tools designed to streamline the therapeutic development lifecycle. The company specializes in predictive platforms that enhance guide RNA design, a fundamental component in the success of CRISPR-based gene editing. By integrating deep learning algorithms with rigorous wet lab capabilities, Cassidy Bio offers a comprehensive solution for researchers struggling with off-target effects and suboptimal design parameters. This dual-pronged approach allows the company to maintain a competitive edge in the rapidly evolving biotech sector, positioning itself as an essential partner for pharmaceutical entities seeking to de-risk their gene-editing pipelines.
How much funding has Cassidy Bio raised?
Cassidy Bio has raised a total of $8M across 1 funding round:
Seed
$8M
Seed (2025): $8M with participation from Ahren Innovation Capital, AstraZeneca, Merck, lool Ventures, and 10d
Key Investors in Cassidy Bio
Ahren Innovation Capital
Ahren Innovation Capital is an investment institution focused on supporting transformational companies at the intersection of deep technology and deep science, providing both patient and active capital.
AstraZeneca
AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines across multiple therapeutic areas.
Merck
Merck & Co., Inc. is a global healthcare company delivering innovative solutions through prescription medicines, biologic therapies, vaccines, and animal health products.
What's next for Cassidy Bio?
With this major enterprise-level funding, Cassidy Bio is poised to scale its operational capacity and expand its reach within the global biopharmaceutical market. The strategic focus will likely shift toward enhancing the predictive accuracy of its AI models and broadening its portfolio of therapeutic applications. By utilizing the recent capital to foster deeper collaborations with industry leaders, the company aims to solidify its role as a foundational technology provider in the gene-editing space. Future growth will be driven by the continued refinement of its platform, enabling faster, more reliable, and highly scalable development cycles for complex genetic medicines.
See full Cassidy Bio company page
